Bvf Partners L P/il sold $174M of KYMR
director, other at Kymera Therapeutics, Inc.. 1,630,658 shares at an average of $106.50, traded Jun 26, 2026, filed Jun 26, 2026.
Score components
- +15RoleDirector
- +25Trade size$173.7M at market
- +20Share of holdings soldSold 58% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000921895-26-001688, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | SOpen-market sale Common Stock, $0.0001 par value | -837,914 | $106.50 | $89M | 1,960,881 | Jun 26, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stock, $0.0001 par value | -627,597 | $106.50 | $67M | 1,592,261 | Jun 26, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stock, $0.0001 par value | -113,289 | $106.50 | $12M | 240,123 | Jun 26, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stock, $0.0001 par valueindirect: See footnote | -51,858 | $106.50 | $5.5M | 78,787 | Jun 26, 2026 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 30Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $6.0M 50,000 shares | -7% | |
| 26Weak | Kymera Therapeutics, Inc. | Noah Goodman Chief Business Officer | $387k 3,389 shares | -7% | |
| 32Weak | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $8.9M 77,109 shares | -24% | |
| 35Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $9.2M 80,000 shares | -11% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $8.3M 76,650 shares | -3% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $56M 513,245 shares | -18% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.4M 31,283 shares | -1% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $44M 398,765 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.